Article

Endogenous secretory receptor for advanced glycation end products and chronic kidney disease in the elderly population.

Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
American Journal of Nephrology (Impact Factor: 2.62). 03/2011; 33(4):313-8. DOI: 10.1159/000324846
Source: PubMed

ABSTRACT The relationship of circulating endogenous secretory receptor for advanced glycation end products (esRAGE) and chronic kidney disease (CKD) has not been well characterized. The aim of the study was to determine whether plasma esRAGE is associated with CKD and is predictive of developing CKD in older adults.
The relationship between plasma esRAGE and CKD (more than stage 3 of the National Kidney Foundation classification; estimated glomerular filtration rate <60 ml/min/1.73 m(2)) and CKD over 6 years of follow-up was examined in a cross-sectional and prospective study design in 1,016 men and women, ≥65 years, in the InCHIANTI study, a population-based cohort study of aging in Tuscany, Italy.
At enrollment, 158 (15.5%) had CKD. Mean (SD) plasma esRAGE was 0.45 (0.24) ng/ml. Plasma esRAGE (ng/ml) was associated with CKD (odds ratio per 1 SD = 1.30; 95% CI 1.1-1.6; p < 0.005) in a multivariable logistic regression model, adjusting for potential confounders. Plasma esRAGE was an independent predictor of incident CKD over 6 years of follow-up (hazard ratio per 1 SD = 1.37; 95% CI 1.1-1.7; p < 0.008) in a multivariable Cox proportional hazards model, adjusting for potential confounders.
Elevated plasma esRAGE is independently associated with CKD and is an independent predictor of incident CKD in older community-dwelling adults.

0 Bookmarks
 · 
64 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Advanced glycation end products (AGEs) was implicated in the pathogenesis of endothelial dysfunction in diabetic vascular complications. Our previous study found that a novel compound 4,4'-diphenylmethane-bis(methyl) carbamate (CM1) from Cortex Mori (Morus alba L.) could attenuate AGEs-induced endothelial dysfunction. The present study was conducted to explore the possible protective mechanisms of CM1 on AGEs-induced endothelium damage. In binding experiments, fluorescence quenching and fluorescence polarization assays showed no significant difference changes of AGEs on fluorescence intensity and polarization in the absence/presence of CM1. In AGEs formation experiments, CM1 was incubated with AGEs precursor compounds methylglyoxal (MGO), glyceraldehydes (Glycer) or glycolaldehyde (Glycol) in the formation system. However, high performance liquid chromatography (HPLC) analysis showed no new conjugated compounds formed in the reaction system. The results of ELISA analysis also showed that CM1 did not inhibit the AGEs formation. However, the pretreatment with CM1 could decrease significantly AGEs or high-mobility group box-1 (HMGB1, a ligand of RAGE)-induced cytotoxicity, apoptosis and reactive oxygen species (ROS) in human umbilical vein endothelial cells (HUVECs). Our results suggested that CM1 might block the AGEs-RAGE signal transduction rather than inhibit AGEs formation or bind to AGEs and change its structure to prevent endothelial dysfunction in diabetic vascular complications.
    Fitoterapia 06/2013; · 2.23 Impact Factor

Full-text (2 Sources)

View
2 Downloads
Available from
May 20, 2014